Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

75.06USD
22 Jun 2018
Change (% chg)

$1.08 (+1.46%)
Prev Close
$73.98
Open
$75.04
Day's High
$75.47
Day's Low
$74.81
Volume
1,744,719
Avg. Vol
1,655,690
52-wk High
$94.19
52-wk Low
$73.21

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 0.79
Market Cap(Mil.): $191,991.41
Shares Outstanding(Mil.): 2,550.62
Dividend: 2.94
Yield (%): 3.62

Financials

  NVS Industry Sector
P/E (TTM): 22.13 29.56 34.14
EPS (TTM): 3.39 -- --
ROI: 7.52 13.56 13.10
ROE: 11.54 15.35 15.09

BRIEF-FDA Allows Label For Novartis' Drug Cosentyx To Include Psoriatic Arthritis Benefit

* NOVARTIS RECEIVES FDA APPROVAL FOR INCLUSION OF NEW EVIDENCE THAT COSENTYX® INHIBITS PROGRESSION OF JOINT STRUCTURAL DAMAGE IN PSORIATIC ARTHRITIS

Jun 19 2018

Novartis touts effectiveness, safety of autoimmune drug copies

ZURICH Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases.

Jun 15 2018

Novartis touts effectiveness, safety of autoimmune drug copies

ZURICH, June 15 Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases. The Swiss drugmaker said Zessly, its Remicade biosimilar, matched the original medicine for safety and efficacy at 54 weeks, including in patients who switched from the original. Switching from

Jun 15 2018

BRIEF-Regenxbio Receives $100 Mln Accelerated License Payment

* REGENXBIO RECEIVES $100 MILLION ACCELERATED LICENSE PAYMENT DUE TO ACQUISITION OF AVEXIS BY NOVARTIS

Jun 11 2018

Novartis readies anti-sexism message for migraine drug

ZURICH With women hardest hit by migraine headaches, Swiss drugmaker Novartis is gearing up its marketing message to counteract sexism that it worries might become a barrier to adoption of its new medicine Aimovig. 

Jun 01 2018

UPDATE 1-Novartis readies anti-sexism message for migraine drug

* Swiss company also considering new pricing models (Recasts story to focus on Novartis strategy, adds comment from chief neurological developer, details throughout)

Jun 01 2018

Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod

ZURICH Novartis's generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines.

Jun 01 2018

Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod

ZURICH, June 1 Novartis's generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines.

Jun 01 2018

BRIEF-Novartis Completes Sale Of Stake In Consumer Healthcare JV To GSK

* COMPLETES SALE OF STAKE IN CONSUMER HEALTHCARE JOINT VENTURE TO GSK FOR USD13.0 BILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 01 2018

BRIEF-GlaxoSmithKline Says Completes Novartis' Consumer Healthcare Buyout

* COMPLETED BUYOUT OF NOVARTIS' 36.5% STAKE IN ITS CONSUMER HEALTHCARE JOINT VENTURE FOR $13 BILLION Source text for Eikon: Further company coverage:

Jun 01 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $122.84 +1.39
Pfizer Inc. (PFE.N) $36.51 +0.21
Merck & Co., Inc. (MRK.N) $61.47 +0.29
Roche Holding Ltd. (ROG.S) CHF216.45 --
Roche Holding Ltd. (RO.S) CHF223.60 +4.00
Abbott Laboratories (ABT.N) $61.94 +0.19
Sanofi SA (SASY.PA) €69.01 --
AstraZeneca plc (AZN.L) 5,229.00 -26.00
GlaxoSmithKline plc (GSK.L) 1,546.00 +7.60
Eli Lilly And Co (LLY.N) $85.92 -0.15

Earnings vs. Estimates